ISRCTN05087777已完成不适用
Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind study
Berna Biotech Ltd (Switzerland)0 个研究点目标入组 50 人开始时间: 2005年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Healthy adults between 18 and 45 years of age.
排除标准
- •Any confirmed or suspected immunosuppressive or immunodeficient condition or prior exposure to ETEC.
研究者
相似试验
尚未招募
不适用
Immunogenicity and safety study of 1,2 doses of GSK Biologicals meningococcal vaccine MenACWY-TT (GSK134612) in toddlersPACTR201408000864165GlaxoSmithKline Biologicals900
已完成
3 期
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in IndiaCTRI/2015/05/005770Sanofi Pasteur SA400
已完成
3 期
The effect of dexmedetomidine on reducing the incidence of cough after extubatioTracheal Extubation.IRCT20180416039326N19Esfahan University of Medical Sciences540
进行中（未招募）
1 期
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570
尚未招募
1 期
Safety, preliminary efficacy and immunogenicity of traditional Chinese medicine miRNA hydrogel in the treatment of eczema: a randomized, double-blind, placebo-controlled, dose-increasing clinical studyeczemaITMCTR2000003604Shanghai Skin Disease Hospital